

REMARKS

Upon entry of this amendment, Claims 1-23 are pending and under consideration. Claims 1-23 are original claims.

Group I has been elected, without traverse. Claims 7-23 are withdrawn from consideration.

I. Restriction and Election under 35 U.S.C. 121

a. Restriction of Groups I(a)

The Office has made a restriction requirement between the following groups:

Group 1(a). Claims 1-6, drawn to a recombinant anticoagulant protein and a method of inhibiting blood coagulation utilizing said protein.

Group 1(b). Claim 10, drawn to a method of treating or preventing an excess thrombotic activity in a subject utilizing said protein.

Additionally, each of the inventions of Groups 1(a), 1(b) and II are directed to the following 4 distinct species.

- (1) SEQ ID NO: 1 or DNA encoding it.
- (2) SEQ ID NO: 2 or DNA encoding it.
- (3) SEQ ID NO: 3 or DNA encoding it.
- (4) SEQ ID NO: 4 or DNA encoding it.

The Office states that in order to be fully compliant to this requirement, the response must include (i) election of a species from Groups 1-4 above or invention from Groups 1(a-b) above to be examined, and (ii) identification of the claims encompassing the elected invention.

b. Election of Groups I(a), without Traverse.

With this response, the Applicants elect Group 1(a) without traverse, which encompasses Claims 1-6. Claims 7-9 and 11-23 are hereby withdrawn from consideration.

II. CONCLUSION

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,

Dated: December 13, 2007

/G. Harley Blosser/

G. Harley Blosser, Reg. No. 33,650

Customer No. 26263

314.259.5806